Literature DB >> 26519364

Late recurrence (more than 10 years) in early (tumors equal to or smaller than 2 cm) breast cancer patients.

J Giuliani1, A Mercanti2, A Bonetti2.   

Abstract

Entities:  

Keywords:  Early breast cancer; Late recurrence; Prognostic factors

Mesh：

Year:  2015        PMID： 26519364     DOI： 10.1007/s12094-015-1433-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  5 in total

Review 1.  Follow-up strategies for women treated for early breast cancer.

Authors:  M P Rojas; E Telaro; A Russo; I Moschetti; L Coe; R Fossati; D Palli; Turco M del Roselli; A Liberati
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

2.  The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival.

Authors:  B B Oven Ustaalioglu; O Balvan; A Bilici; A Develi; M Aliustaoglu; F A Vardar; B Erkol
Journal:  Clin Transl Oncol       Date:  2015-06-17       Impact factor: 3.405

3.  The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.

Authors:  Martin Filipits; Torsten O Nielsen; Margaretha Rudas; Richard Greil; Herbert Stöger; Raimund Jakesz; Zsuzsanna Bago-Horvath; Otto Dietze; Peter Regitnig; Christine Gruber-Rossipal; Elisabeth Müller-Holzner; Christian F Singer; Brigitte Mlineritsch; Peter Dubsky; Thomas Bauernhofer; Michael Hubalek; Michael Knauer; Harald Trapl; Christian Fesl; Carl Schaper; Sean Ferree; Shuzhen Liu; J Wayne Cowens; Michael Gnant
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

4.  Evaluation of factors related to late recurrence--later than 10 years after the initial treatment--in primary breast cancer.

Authors:  Reiki Nishimura; Tomofumi Osako; Yasuyuki Nishiyama; Rumiko Tashima; Masahiro Nakano; Mamiko Fujisue; Yasuo Toyozumi; Nobuyuki Arima
Journal:  Oncology       Date:  2013-07-17       Impact factor: 2.935

5.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Authors:  I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.